E-selectin

GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, E-selectin, Female, Internal medicine, MD Anderson Cancer Center, MD, Azacitidine, Risk, Society, CRi, Blood, Patient, Science, CR, Cancer, NF-κB, MFC, Transplant, Cladribine, Myelocyte, Division, FDA, Aza, Survival, LDAC, UC Davis School of Medicine, AML, Breakthrough therapy, Inflammation, Nature, Safety, University, ELN, Acute myeloid leukemia, Carbohydrate, Mathematical fallacy, ECOG, ASH, Male, Pharmaceutical industry, Glycomimetic, Venetoclax

These results were presented at the 64th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • These results were presented at the 64th American Society of Hematology (ASH) Annual Meeting.
  • The studies describe safety and preliminary efficacy in frontline unfit and treated secondary AML populations not previously studied with this novel investigational agent, said Edwin Rock, M.D., Ph.D., Chief Medical Officer.
  • These presentations provide the first uproleselan clinical data in AML generated outside of company-sponsored studies.
  • A majority of 15 patients enrolled were male (n=10) with ECOG status of less than 2 (ECOG 0=1; 1=10; 2=4).

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Review, Forward-looking statement, Adult, IRB, Carbohydrate, National Cancer Institute, Risk, Nasdaq, Society, Acute myeloid leukemia, Breakthrough therapy, Blood, Cancer, SEC, NF-κB, Safety, U.S. Securities and Exchange Commission, Myelocyte, Survival, Inflammation, D, Science, AML, Clinical trial, Research, Patient, DMC, Institutional review board, ASH, E-selectin, MD, NCI, FDA, Pharmaceutical industry, Air cargo, Glycomimetic

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2022.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2022.
  • The NCI will determine the timing and medical meeting to present the full results of the Phase 2 study.
  • Third Quarter 2022 Financial Results:
    Cash position: As of September 30, 2022, GlycoMimetics had cash and cash equivalents of $51.6 million as compared to $90.3 million as of December 31, 2021.
  • R&D Expenses: Research and development expenses decreased to $4.9 million for the quarter ended September 30, 2022, as compared to $13.3 million for the same period in 2021.

GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Health, Oncology, Clinical Trials, Bone marrow, Food, Society, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough therapy, Cell, Safety, Adult, Terminology, ASH, Acute myeloid leukemia, Nasdaq, Transplant, Inflammation, U.S. Securities and Exchange Commission, Forward-looking statement, Cancer, Carbohydrate, AML, E-selectin, Patient, MD, Poster, Cellular, Pharmaceutical industry, Dentistry, Glycomimetic

These presentations provide the first uproleselan clinical data generated outside of company-sponsored studies.

Key Points: 
  • These presentations provide the first uproleselan clinical data generated outside of company-sponsored studies.
  • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
    Session Name: 616.
  • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
    Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted inhibitor of E-selectin.
  • GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need.

Ambulero Finishes Second for Prestigious Cade Prize

Retrieved on: 
Tuesday, October 11, 2022
Health, Genetics, Clinical Trials, Research, Science, Cardiology, Biotechnology, Blood, Degenerative disease, National Inventors Hall of Fame, Patient, Biotechnology, Jackson Memorial Hospital, Research, Regeneration, Professor, Technology, University, Private Securities Litigation Reform Act, Vascular disease, Company, Creativity, Department, Cade Museum for Creativity and Invention, E-selectin, Chair, Amputation, FACS, FDA, Risk, Toxicology, Pharmaceutical industry, Medicine, DRS

Ambulero, Inc., a Miami, Florida-based biotechnology company, a spinout from the University of Miami Miller School of Medicine (Ambulero or the Company) developing new gene and cell therapy treatments for severe vascular disease, finished second for the prestigious Cade Prize out of 85 technology and healthcare companies developed from university technology in Florida, Georgia, and Alabama.

Key Points: 
  • Ambulero, Inc., a Miami, Florida-based biotechnology company, a spinout from the University of Miami Miller School of Medicine (Ambulero or the Company) developing new gene and cell therapy treatments for severe vascular disease, finished second for the prestigious Cade Prize out of 85 technology and healthcare companies developed from university technology in Florida, Georgia, and Alabama.
  • We are very excited about our great reception during the Cade Prize competition.
  • The Cade Prize was created in 2009 and is given annually to top companies who have been spun out of Florida, Georgia, and Alabama universities.
  • The prize was named for Robert Cade, M.D., who was a Professor of Medicine at the University of Florida Medical School and the inventor of the sports drink, Gatorade.

Ambulero Receives Positive Pre-IND Response from FDA for AMB-301 Treatment of Rare Vascular Disease

Retrieved on: 
Tuesday, September 27, 2022
Biotechnology, FDA, Health, Genetics, Clinical Trials, E-selectin, Degenerative disease, FDA, Company, Private Securities Litigation Reform Act, DRS, Patient, Amputation, Risk, CEO, Tissue, Pharmacology, Research, Vascular disease, University, Pharmaceutical industry

Ambulero, Inc., a Miami, Florida-based spinout from the University of Miami Miller School of Medicine (Ambulero or Company) developing new gene and cell therapies for severe vascular disease, announces it received a positive response from a Type B Pre-IND meeting with the FDA to develop AMB-301 as a treatment for a rare vascular condition called Buergers Disease.

Key Points: 
  • Ambulero, Inc., a Miami, Florida-based spinout from the University of Miami Miller School of Medicine (Ambulero or Company) developing new gene and cell therapies for severe vascular disease, announces it received a positive response from a Type B Pre-IND meeting with the FDA to develop AMB-301 as a treatment for a rare vascular condition called Buergers Disease.
  • Buergers disease is a debilitating vascular disease that can lead to severe limb damage and amputation, often in young patients.
  • Robert L. Buchanan, CEO of Ambulero, commented, This is our second positive interaction with the FDA in less than a year.
  • Ambulero is a privately-held biotechnology company advancing a new gene and cell therapy platform to treat serious vascular diseases.

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Health, Pharmaceutical, Cardiology, Oncology, Inflammation, University, Astex, Physician, Lymphatic system, Cancer, Research, Form 10-K, Carbohydrate, Food and Drug Administration, Hematology, GSK, AML, Macrogen, Risk, Food, Stanford University School of Medicine, SEC, Chemistry, Acute myeloid leukemia, Cell, U.S. Securities and Exchange Commission, Swarthmore College, Immunology, MD, Economics, Margetuximab, Nasdaq, FDA, Breakthrough therapy, Doctor of Philosophy, Company, Adult, E-selectin, Stanford University, Annual report, Bone marrow, Forward-looking statement, Patient, CMO, Pharmaceutical industry, Glycomimetic, Microbiology, Biology, Brigham

GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO).

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO).
  • We are thrilled to have Ed join the GlycoMimetics team.
  • He completed medical residency training at Brigham and Womens Hospital in Boston, MA, a medical oncology fellowship at the University of Pennsylvania, and a postdoctoral fellowship in vaccine engineering at Stanford.
  • Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022

Retrieved on: 
Wednesday, August 3, 2022
Biotechnology, Health, Pharmaceutical, Cardiology, Oncology, NCI, Projection, U.S. Securities and Exchange Commission, MD Anderson Cancer Center, Nasdaq, University, SCD, Clinical trial, Chemistry, Inflammation, MD, Cancer, Bone marrow, Washington University in St. Louis, Volatile organic compound, SEC, D, Adult, Annual report, Partnership, Disclosure, Patient, Carbohydrate, IND, Form 10-K, Forward-looking statement, National Cancer Institute, Breakthrough therapy, Research, FDA, Risk, AML, E-selectin, Cell, Acute myeloid leukemia, Company, University of California, Davis, IV, Pharmaceutical industry, Tutoring, Glycomimetic, St. Louis

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the second quarter ended June 30, 2022.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the second quarter ended June 30, 2022.
  • Cash and cash equivalents as of the end of the quarter were $60.2 million.
  • In June, GlycoMimetics received clearance from the FDA of an IND application for clinical development of GMI-1687 in SCD.
  • Second Quarter 2022 Financial Results:
    Cash position: As of June 30, 2022, GlycoMimetics had cash and cash equivalents of $60.2 million as compared to $90.3 million as of December 31, 2021.

Evox Therapeutics Presents Progress Across its DeliverEX™ Exosome Therapeutics Platform with Nine Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Doxorubicin, PBS, Organic acid, Lysosomal storage disease, Engineering, Transferrin, Company, International Society, Spleen, ISEV, Neoplasm, International Society for Extracellular Vesicles, ERT, Seminal vesicles, Endothelium, Ligand, Inflammation, Antibody, Therapy, E-selectin, Exosome, GAA, Half-life, Liver, Degenerative disease, Comparison, ABS, Neutralizing antibody, Cell, Cell biology, Mouse, Glycogen storage disease type II, CNS, Brain, Plasma, EVS, BBB, FC, RNA, Central nervous system, Technology, South Luzon Expressway, Enzyme replacement therapy, Trehalose, Protein, Oxford, GLOBE, Tissue, Muscle, Pharmaceutical industry, Wood drying, Vaccine, Fine chemical

In parallel, we are also focused on advances in exosome manufacturing, including exploring new ways to produce exosome therapeutics.

Key Points: 
  • In parallel, we are also focused on advances in exosome manufacturing, including exploring new ways to produce exosome therapeutics.
  • We believe our advances will allow exosome therapeutics access to cellular compartments and tissues that are currently out of reach using other approaches.
  • This could provide significant benefit for both creating feasible dosing regimens and to ensure sufficient plasma residence time for tissue-specific targeting.
  • Engineered display of ligands on the surface of exosomes can be used to increase specific targeting of exosomes to desired tissues.

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Adult, Sickle cell disease, Bone marrow, Inflammation, U.S. Securities and Exchange Commission, GMP, Sale, MD Anderson Cancer Center, Cancer, Patient, Annual report, Nasdaq, Breakthrough therapy, E-selectin, FDA, IND, Cell, Food, Risk, Chemistry, Forward-looking statement, National, Clinical trial, NCI, Company, Carbohydrate, Senior, D, Food and Drug Administration Amendments Act of 2007, MDS, AML, GLP, Acute myeloid leukemia, Research, University, University of California, Davis, Trial of the century, Washington University in St. Louis, SEC, National Cancer Institute, VOC, Form 10-K, Workforce, Safety, Online gambling, Pharmaceutical industry, Internet service provider, Glycomimetic, St. Louis

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the first quarter ended March 31, 2022.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the first quarter ended March 31, 2022.
  • During the first quarter, we advanced our transformation from a research company to a commercially-focused organization.
  • Based on current projections, GlycoMimetics now anticipates mid-year 2023 for the overall survival events trigger, with top line data disclosure shortly thereafter.
  • First Quarter 2022 Financial Results:
    Cash position: As of March 31, 2022, GlycoMimetics had cash and cash equivalents of $76.5 million as compared to $90.3 million as of December 31, 2021.

Vasculitis Pipeline Insights Report 2022: Comprehensive Insights about 40+ Companies and 40+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Health, Pharmaceutical, Giant, Amputation, NDA, GCA, News, C5a, Giant cell arteritis, Clinical trial, Axial spondyloarthritis, Antidepressant discontinuation syndrome, ANCA, B-cell activating factor, Research, Psoriasis, Giant cell, Novartis, Route of administration, E-selectin, Route, Inflammation, Time-invariant system, III, Psoriatic arthritis, Inactive, AAV, Technology, Discovery, Secukinumab, Blood, ROA, Belimumab, Administration, Acquisition, Vascular disease, Regeneration, Survival, Medical device, Pharmaceutical industry, Vaccine, Vasculitis

The "Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.

Key Points: 
  • The "Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.
  • The assessment part of the report embraces, in depth Vasculitis commercial assessment and clinical assessment of the pipeline products under development.
  • Companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D.
  • Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.